Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Multiple myeloma treatment patterns in China: Analysis of the CancerMPact treatment architecture database

Megan Epperson, Luan Luan, Patrick Hlavacek, Mohammed Ashraf Chaudhary, Didem Aydin, Marco Dibonaventura

Blood (2025) 146 (Supplement 1): 8118.

https://doi.org/10.1182/blood-2025-8118

Published: 2025

Journal Articles

Real-world treatment patterns of elranatamab in patients with multiple myeloma in Japan: Findings from the EVEREST study

Satoshi Yoshihara, Aster Meche, Patrick Hlavacek, Ann-Sophie Demers, Sarasa MA Johnson, Guido Nador, Shohei Ikoma, Chandra Prakash Yadav, Carla AL Assaf, Marco Dibonaventura, Yong Chen

Blood (2025) 146 (Supplement 1): 2801.

https://doi.org/10.1182/blood-2025-2801

Published: 2025

Journal Articles

Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study

Thomas LeBlanc, Rakesh Popat, C. Kennedy, Josh Coulter, Lewis Kopenhafer, William You, Kathleen Beusterien, David Hughes, Guido Nador, Joseph C Cappelleri, Marco Dibonaventura, Mohsena Sumaya, Patrick Hlavacek

Blood (2025) 146 (Supplement 1): 2631.

https://doi.org/10.1182/blood-2025-2631

Published: 2025

Journal Articles

Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens

Sarasa MA Johnson, Francis Vekeman, Luan Luan, Patrick Hlavacek, Aster Meche, Chai Hyun Kim, Paul Cislo, Didem Aydin, Marco Dibonaventura

Blood (2025) 146 (Supplement 1): 8128.

https://doi.org/10.1182/blood-2025-8128

Published: 2025

Journal Articles

Real-world characteristics of patients initiating elranatamab for relapsed/refractory multiple myeloma in the United States

Aster Meche, Charlotte Aubrac, Sarasa MA Johnson, Patrick Hlavacek, David Hughes, Guido Nador, Chandra Prakash Yadav, Marco Dibonaventura, Yong Chen

Blood (2025) 146 (Supplement 1): 8144.

https://doi.org/10.1182/blood-2025-8144

Published: 2025

Journal Articles

Real-world step-up dosing of patients receiving elranatamab for multiple myeloma in Japan

Satoshi Yoshihara, Ariane Faucher, Sarasa MA Johnson, Aster Meche, Patrick Hlavacek, Guido Nador, Shohei Ikoma, Chenan Zhang, Chandra Prakash Yadav, Carla AL Assaf, Marco Dibonaventura, Yong Chen

Blood (2025) 146 (Supplement 1): 8143.

https://doi.org/10.1182/blood-2025-8143

Published: 2025

Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study - Interim Results

Charis Charalampous, Shaji Kumar, Ricardo D. Parrondo, Saurabh Chhabra, Madhu Nagaraj, Mei Sheng Duh, Priyanka J. Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Rickard Sandin, Joseph C. Cappelleri, David Hughes, Guido Nador, Marco DiBonaventura

Blood (2024) 144 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2024-204005

Published: 2024

Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M.A. Johnson, Francis Vekeman, Patrick Hlavacek, Aster Meche, Paul Cislo, David Hughes, Guido Nador, Marco DiBonaventura

Blood (2024) 144 (Supplement 1): 2401.

https://doi.org/10.1182/blood-2024-203920

Published: 2024

Journal Articles

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Kathy Annunziata, Nikoletta Sternbach, Hitomi Tanaka, Marco DiBonaventura, Joseph C. Cappelleri, Jack Watkins, David Hughes, Aster Meche, Chai Hyun Kim, C. Todd Kennedy, Hans Scheurer, Thomas W. LeBlanc

Blood (2024) 144 (Supplement 1): 3762.

https://doi.org/10.1182/blood-2024-201802

Published: 2024

Journal Articles

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Mohamad Mohty, Nizar J. Bahlis, Ajay K. Nooka, Marco DiBonaventura, Joseph C. Cappelleri, Umberto Conte

Blood (2024) 144 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2024-203723

Published: 2024

Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

Charalampos Charalampous, Shaji Kunnathu Kumar, Ricardo Parrondo, Saurabh Chhabra, Mei Sheng Duh, Priyanka Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Jinma Ren, Alex Schepart, Guido Nador, Marco DiBonaventura

Blood (2023) 142 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2023-180984

Published: 2023

Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco DiBonaventura

Blood (2023) 142 (Supplement 1): 6716.

https://doi.org/10.1182/blood-2023-180848

Published: 2023

Journal Articles

Treatment Patterns and Hydroxyurea Response Among Patients with Polycythemia Vera

Shreekant Parasuraman, PhD, Marco DiBonaventura, PhD, Kelly Reith, MS,MBA, Kristen Concialdi, BA

Blood (2014) 124 (21): 1852.

https://doi.org/10.1182/blood.V124.21.1852.1852

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Multiple myeloma treatment patterns in China: Analysis of the CancerMPact treatment architecture database

Real-world treatment patterns of elranatamab in patients with multiple myeloma in Japan: Findings from the EVEREST study

Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study

Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens

Real-world characteristics of patients initiating elranatamab for relapsed/refractory multiple myeloma in the United States

Real-world step-up dosing of patients receiving elranatamab for multiple myeloma in Japan

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study - Interim Results

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Treatment Patterns and Hydroxyurea Response Among Patients with Polycythemia Vera

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only